Advertisement
Screener

Fractyl Health, Inc. (GUTS) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Fractyl Health, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Fractyl Health, Inc. (GUTS) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$16.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-10

  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$25.54M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $9.22M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$43.73M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$45.60M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$140.95M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$68.69M.
  • Fractyl Health, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$77.09M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30-$25.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$16.32M
10-Q · filed 2026-08-10
-$60.05M
derived: sum of 3 quarters · filed 2026-08-10
-$105.65M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$9.22M
10-Q · filed 2026-05-12
-$34.51M
derived: sum of 2 quarters · filed 2026-05-12
-$80.11M
derived: sum of 3 quarters · filed 2026-05-12
-$108.00M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$43.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$89.33M
derived: sum of 2 quarters · filed 2026-03-24
-$117.22M
derived: sum of 3 quarters · filed 2026-08-10
-$140.95M
10-K · filed 2026-03-24
2025-09-30-$45.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$73.49M
derived: sum of 2 quarters · filed 2026-08-10
-$97.23M
10-Q · filed 2025-11-12
-$122.20M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$27.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$51.62M
10-Q · filed 2026-08-10
-$76.59M
derived: sum of 3 quarters · filed 2026-08-10
-$99.77M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$23.73M
10-Q · filed 2026-05-12
-$48.70M
derived: sum of 2 quarters · filed 2026-05-12
-$71.88M
derived: sum of 3 quarters · filed 2026-05-12
-$89.11M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$24.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$48.14M
derived: sum of 2 quarters · filed 2026-03-24
-$65.37M
derived: sum of 3 quarters · filed 2026-03-24
-$68.69M
10-K · filed 2026-03-24
2024-09-30-$23.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$40.40M
derived: sum of 2 quarters · filed 2025-11-12
-$43.72M
10-Q · filed 2025-11-12
-$62.90M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$17.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$20.55M
10-Q · filed 2025-08-12
-$39.73M
derived: sum of 3 quarters · filed 2025-08-12
-$55.48M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$3.32M
10-Q · filed 2025-05-13
-$22.50M
derived: sum of 2 quarters · filed 2025-05-13
-$38.25M
derived: sum of 3 quarters · filed 2025-05-13
-$68.48M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$19.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
-$34.93M
derived: sum of 2 quarters · filed 2025-03-03
-$65.16M
derived: sum of 3 quarters · filed 2025-03-03
-$77.09M
10-K · filed 2025-03-03
2023-09-30-$15.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$45.98M
derived: sum of 2 quarters · filed 2024-11-12
-$57.91M
10-Q · filed 2024-11-12
2023-06-30-$30.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$42.16M
10-Q · filed 2024-08-14
2023-03-31-$11.93M
10-Q · filed 2024-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
RenovoRx, Inc. (RNXT)United States$0.076B-3.62
Pulmonx Corp (LUNG)United States$0.082B-1.16
CVRx, Inc. (CVRX)United States$0.067B-2.62
DarioHealth Corp. (DRIO)$0.066B-1.39
SkinHealth Systems Inc. (SKIN)United States$0.086B-3.17
LENSAR, Inc. (LNSR)United States$0.087B2.02
Microbot Medical Inc. (MBOT)$0.089B-7.97
TELA Bio, Inc. (TELA)United States$0.057B-0.82
Xtant Medical Holdings, Inc. (XTNT)United States$0.053B
Spectral AI, Inc. (MDAI)United States$0.052B